Results 31 to 40 of about 5,926 (192)

Assessment of the PARP inhibitor talazoparib photosafety profile

Biomedicine & Pharmacotherapy, 2023
Talazoparib (TLZ) is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor employed for the treatment of breast cancer. This drug displays an absorption band in the UVA region, and therefore investigation of the possible phototoxic side-effects associated to its administration results of enormous relevance. In this context, we describe here a
Alejandro Mateos-Pujante, M. Consuelo Jiménez, Inmaculada Andreu   +2 more
openaire   +3 more sources

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers

Molecules, 2023
The protein PARP1, which plays a crucial role in DNA repair processes, is an attractive target for cancer therapy, especially for BRCA-deficient cancers.
Fengqin Yan, Zhenfu Fu, Guo Li, Zhiguo Wang   +3 more
doaj   +1 more source

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors [PDF]

, 2019
The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (QTc) and (ii) to examine the relationship between plasma ...
Plotka, Anna, Chakrabarti, Jayeta, Wang, Diane, Wainberg, Zev A, Hoffman, Justin, Kanamori, David, Naraine, Adriana Milillo, Nguyen, Linh, Moroose, Rebecca   +8 more
core   +1 more source

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

BMC Cancer, 2022
Background Management of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in most cases.
Sayani Bhattacharjee, Matthew J. Sullivan, Rebecca R. Wynn, Alex Demagall, Andrew S. Hendrix, Puneet Sindhwani, Firas G. Petros, Nagalakshmi Nadiminty   +7 more
doaj   +1 more source

Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia

AMB Express, 2019
Due to its potent cytotoxicity in BRCA-mutated tumors, synthetic lethality elicited by poly (ADP-ribose) polymerase (PARP) inhibitor gives renewed enthusiasm to researching and developing anti-cancer therapies. Chronic myeloid leukemia (CML) is a type of
Yuanyuan Liu, Hong Song, Huanqing Song, Xiaoxia Feng, Chuan Zhou, Zhifang Huo   +5 more
doaj   +1 more source

DNArepairK: An Interactive Database for Exploring the Impact of Anticancer Drugs onto the Dynamics of DNA Repair Proteins

Biomedicines, 2021
Cells are constantly exposed to numerous mutagens that produce diverse types of DNA lesions. Eukaryotic cells have evolved an impressive array of DNA repair mechanisms that are able to detect and repair these lesions, thus preventing genomic instability.
Yordan Babukov, Radoslav Aleksandrov, Aneliya Ivanova, Aleksandar Atemin, Stoyno Stoynov   +4 more
doaj   +1 more source

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

Frontiers in Oncology, 2023
PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system.
Víctor Albarrán, Jesús Chamorro, Javier Pozas, María San Román, Diana Isabel Rosero, Cristina Saavedra, María Gion, Alfonso Cortés, Elena Escalera, Eva Guerra, Elena López Miranda, María Fernández Abad, Noelia Martínez Jañez   +12 more
doaj   +1 more source

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

BMC Cancer, 2020
Background PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells.
Verena Weigert, Tina Jost, Markus Hecht, Ilka Knippertz, Lucie Heinzerling, Rainer Fietkau, Luitpold V. Distel   +6 more
doaj   +1 more source

Supplementary table 2.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies

, 2021
Supplementary Table 2. Exposure to talazoparib (safety population).
Adrian Bloor (3520115), Ajay K Gopal (11598880), Mark Juckett (11598895), Ying Chen (9697), Rakesh Popat (8859863), Terry Gaymes (11598889), Tobias Menne (11598886), Ryan J Mattison (11598883), Asim Khwaja (11598892), Matthew J Cotter (11598898), Ghulam J Mufti (9332201)   +10 more
core   +1 more source

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment [PDF]

, 2022
AIM: This phase I study investigated talazoparib pharmacokinetics (PK) and safety in patients with advanced solid tumours and varying degrees of hepatic function.
Plotka, Anna, Shi, Haihong, Durairaj, Chandrasekar, Wang, Diane D., Guo, Cen, Yu, Yanke, Chandrasekar Durairaj, Chakrabarti, Jayeta, Wainberg, Zev A, Sarina A. Piha‐Paul, Wang, Diane D, Yanke Yu, Haihong Shi, Piha‐Paul, Sarina A., Diane D. Wang, Cen Guo, Jayeta Chakrabarti, Rebecca Moroose, Wainberg, Zev A., Piha‐Paul, Sarina A, Anna Plotka, Moroose, Rebecca, Zev A. Wainberg   +22 more
core   +1 more source